# Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

> **NCT05305911** · PHASE2 · RECRUITING · sponsor: **Minneapolis Heart Institute Foundation** · enrollment: 81 (estimated)

## Conditions studied

- Heart Attack
- Enlarged Heart

## Interventions

- **DRUG:** SGLT-2 inhibitors
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05305911
- **Lead sponsor:** Minneapolis Heart Institute Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-03
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2024-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05305911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05305911, "Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05305911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*